Jeff Huber
Angel Investor · at Triatomic Capital
Menlo Park, United States
Jeff Huber is a seed investor at Triatomic Capital in Menlo Park focused on Biotechnology and Computer. Jeff Huber is the Founding CEO and Vice Chairman of GRAIL (2016-present). GRAIL's mission is to detect cancer early, when it can be cured.Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google's life sciences efforts in Google[x] (2013-2016), and led development and scaling for GoogleMaps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology companies, including Openwater, Mammoth Biosciences, Vir, Sana, Zymergen, Atomwise, Genalyte, Pinterest, Honor, OpenDoor, and AngelList.Jeff holds a bachelor's degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a 'Distinguished Alumni Award' from the College of Electrical & Computer Engineering (2018) for 'challenging the status quo through innovation'. He also holds a master's degree in business from Harvard University. Jeff is a board member of GRAIL (Vice Chairman), Genalyte (Chairman), Electronic Arts (EA), Openwater, and The Exploratorium, and a former board member of Illumina (ILMN; 2014-2016). He is Managing Director at Triatomic Capital.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Jeff Huber invests in
Stages Jeff Huber invests in
Countries Jeff Huber invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (36%)
- Computer 3 (27%)
- Software 3 (27%)
- Health Care 3 (27%)
- Therapeutics 2 (18%)
Stage
- Seed 4 (36%)
- Series A 3 (27%)
- Post-IPO Equity 2 (18%)
- Pre-Seed 1 (9%)
- Series C 1 (9%)
Country
- United States 9 (82%)
- India 1 (9%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials.Zapata Computing is a spun out of Harvard Universitylaunched by a group of Harvard scientists, including Alán Aspuru-Guzik.The company was founded in 2017 and is headquartered in Boston, Massachusetts. | $15M / Post-IPO Equity / Apr 08, 2026 | ||
| D-Matrix is developing a platform that enables data centers to handle large-scale generative AI inference with high throughput and low latency. The company’s offering includes the Corsair™ inference accelerator card, the JetStream™ I/O networking accelerator, and the SquadRack™ rack-scale system, all designed to work together to deliverefficient inference compute. Their technology brings memory and compute closer together, embedding processing inside memory to reduce data movement, improve speed, and energy efficiency. The stack also includes software tools for deployment, model debugging, and performance monitoring, enabling enterprises to scale inference workloads across models and usage scenarios. | $275M / Series C / Nov 12, 2025 | ||
| Coworker.ai is an AI platform designed to automate tasks and streamline workflows within businesses. It integrates with over 40 enterprise applications, eliminating the need for custom coding. The platform focuses on providing context-aware assistance, enabling it to answer questions, plan, and execute tasks. | $13M / Seed / May 20, 2025 | ||
| Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. | $235M / Post-IPO Equity / Sep 11, 2024 | ||
| BetterOmics is a SaaS platform that empowers professionals in the life sciences industry with cutting-edge AI and computational techniques. Betteromics is implemented as a Private SaaS within your Virtual Private Cloud (VPC), allowing you to establish connections across all your data sources. Betteromics also enables every role within your team toaccess a centralized, objective source of truth, empowering them with the ability to create accurate and reliable descriptions.Established by experienced executives from Google and GRAIL, the company comprises a group of dedicated professionals driven by a common mission. They bring together expertise from academia, science, and technology sectors. | $20M / Series A / Oct 26, 2023 | ||
| Manifold Bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement-driven design. The company is building a protein barcoding platform to bring the power of multiplexed measurement to thedevelopment of protein therapeutics.It was founded in 2020 and headquartered in Boston, Massachusetts. | $40M / Series A / Jun 13, 2022 | ||
| Synapticure provides neurodegenerative disease patients with disease specialist and wrap around care, no matter where you live in the US. Founded by patients, we support Dementia, Parkinson's, ALS and more with everyone from on-demand disease-specific neurologists to SLT to 24/7 care coordination and support. | $6M / Seed / Feb 01, 2022 | ||
| Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordablepoint-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.Mammoth has also been working on developing a rapid COVID-19 test. | $23M / Series A / Jul 31, 2018 | ||
| Industrial Microbes designs and builds microbes that produce better chemicals with lower costs and lower carbon emissions. We use greenhouse gases as the raw materials, including biogas, natural gas, and carbon dioxide. We scale our process with global chemical producers. | $120K / Pre-Seed / Jun 15, 2015 | ||
| Razorpay is a platform that enables businesses to accept, process, and disburse payments with its product suite. It gives access to all payment modes including credit card, debit card, net banking, UPI and popular wallets including JioMoney, Mobikwik, Airtel Money, FreeCharge, Ola Money, and PayZapp.The company was founded in 2014 and isheadquartered in Bangalore, Karnataka. | $2.6M / Seed / Mar 23, 2015 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Jeff Huber invest in?
Jeff Huber invests primarily in Biotechnology, Computer and Software startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeff Huber?
Public channels for Jeff Huber include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jeff Huber last invest?
The most recent investment recorded for Jeff Huber closed in Apr 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
